Clinical Trials Details

S1616 (Melanoma)

A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an ANTI-PD1 or ANTI-PD-L1 Agent

Objective

This clinical trial was closed to new patient accrual on July 15, 2020.

Clinical Trial Categories

• Cancers and Other Neoplasms